Literature DB >> 19598149

Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer.

Yong Wha Moon1, Sun Young Rha, Xianglan Zhang, Hei-Cheul Jeung, Woo Ick Yang, Obin Kwon, Jae Heon Jeong, Sung Hah Cheon, Nae Choon Yoo, Hyun Cheol Chung.   

Abstract

BACKGROUND: Dystroglycan (DG) is a recently focused adhesion molecule with possible roles in cancer development and progression. We investigated correlations between alpha-DG expression and prognosis in gastric carcinoma with liver metastasis.
METHODS: For 40 patients with gastric adenocarcinoma and liver-only metastasis, alpha-DG expression was determined by immunohistochemistry in paraffin-embedded surgical specimens of resected stomach tumor, resected liver metastasis, and their normal counterpart tissues. Correlations between alpha-DG expression and prognosis were retrospectively analyzed.
RESULTS: alpha-DG expression was higher in primary gastric cancer (P = 0.006) and lower in liver metastasis (P = 0.002) than in each normal counterpart. In primary stomach cancer, patients who had lower alpha-DG expression in tumors than in normal counterparts showed poor overall survival (OS) (P = 0.028). In contrast, in the liver, patients who had higher alpha-DG expression in tumors than in normal counterparts showed poor OS (P = 0.022). Also, higher alpha-DG expression in liver metastasis than in stomach tumors led to poor recurrence-free survival (P = 0.023) and OS (P = 0.056).
CONCLUSIONS: This approach may be used to further understanding of the pathogenesis of liver metastasis from gastric cancer. Further studies are warranted to reveal the mechanisms of alpha-DG dysregulation in liver metastasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19598149     DOI: 10.1002/jso.21347

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Reduction of α-dystroglycan expression is correlated with poor prognosis in glioma.

Authors:  Xin Zhang; Xiang-Hui Dong; Yue Ma; Lan-Feng Li; He Wu; Min Zhou; Yun-He Gu; Guo-Zhong Li; De-Sheng Wang; Xiao-Feng Zhang; Jing Mou; Ji-Ping Qi
Journal:  Tumour Biol       Date:  2014-08-20

2.  Dystroglycan is associated with tumor progression and patient survival in gastric cancer.

Authors:  Jian Guo Shen; Chao Yang Xu; Xin Li; Ming Jun Dong; Zi Nong Jiang; Jin Wang; Lin Bo Wang
Journal:  Pathol Oncol Res       Date:  2011-06-22       Impact factor: 3.201

3.  Loss of LARGE2 disrupts functional glycosylation of α-dystroglycan in prostate cancer.

Authors:  Alison K Esser; Michael R Miller; Qin Huang; Melissa M Meier; Daniel Beltran-Valero de Bernabé; Christopher S Stipp; Kevin P Campbell; Charles F Lynch; Brian J Smith; Michael B Cohen; Michael D Henry
Journal:  J Biol Chem       Date:  2012-12-06       Impact factor: 5.157

4.  High LARGE1 Expression May Predict Benefit from Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer.

Authors:  Yu Liu; Shirui Huang; Mengjiao Kuang; Huiyan Wang; Qipeng Xie
Journal:  Pharmgenomics Pers Med       Date:  2021-01-18

5.  Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD associate with increased mortality in clear cell renal cell carcinoma.

Authors:  Michael R Miller; Deqin Ma; James Schappet; Patrick Breheny; Sarah L Mott; Nadine Bannick; Eric Askeland; James Brown; Michael D Henry
Journal:  Mol Cancer       Date:  2015-07-30       Impact factor: 27.401

6.  VHL-dependent regulation of a β-dystroglycan glycoform and glycogene expression in renal cancer.

Authors:  Vassilis Aggelis; Rachel A Craven; Jianhe Peng; Patricia Harnden; Lana Schaffer; Gilberto E Hernandez; Steven R Head; Eamonn R Maher; Robert Tonge; Peter J Selby; Rosamonde E Banks
Journal:  Int J Oncol       Date:  2013-08-21       Impact factor: 5.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.